Hikal Ltd.
Snapshot View

252.70 +21.55 ▲9.3%

24 June 2022, 04:01:00 PM
Volume: 139,093

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.hikal.com
Market Cap 3,115.81 Cr.
Enterprise Value(EV) 3,741.16 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 13.02 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 19.41 Trailing Twelve Months Ending 2022-03
Industry PE 29.69 Trailing Twelve Months Ending 2022-03
Book Value / Share 86.62 Trailing Twelve Months Ending 2022-03
Price to Book Value 2.92 Calculated using Price: 252.70
Dividend Yield 0.63 Period Ending 2021-03
No. of Shares Subscribed 12.33 Cr. 123,300,750 Shares
FaceValue 2
Company Profile
Established in 1988 Hikal is a reliable partner to companies in the Pharmaceuticals, Biotech, Agrochemicals and Specialty Chemicals industries. They provide world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner. Their advanced infrastructure has been inspected and approved by globally recognized bodies such as the USFDA.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+9.32%
1 Week
+9.87%
1 Month
-35.49%
3 Month
-35.91%
6 Month
-50.11%
1 Year
-46.78%
2 Year
+102.40%
5 Year
+82.72%
10 Year
+567.28%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 7.60 17.27 9.81 9.32 12.74 12.12 14.46 10.74 15.22
Return on Capital Employed (%) 10.44 17.77 12.50 11.92 11.87 12.81 15.25 12.44 16.15
Return on Assets (%) 2.17 5.17 3.12 3.17 5.02 5.15 6.11 4.62 6.84

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 450 505 532 564 605 669 756 817 933 1,068
Non Curr. Liab. 238 298 242 337 324 312 359 410 379 376
Curr. Liab. 503 479 530 397 470 616 659 653 703 769
Minority Int.
Equity & Liab. 1,191 1,282 1,304 1,298 1,400 1,597 1,775 1,879 2,016 2,213
Non Curr. Assets 782 775 791 808 793 851 888 1,048 1,091 1,249
Curr. Assets 409 507 513 490 607 746 886 831 925 964
Misc. Exp. not W/O
Total Assets 1,191 1,282 1,304 1,298 1,400 1,597 1,775 1,879 2,016 2,213

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 660 829 872 926 1,014 1,296 1,590 1,507 1,720 1,943
Other Income 6 34 2 2 3 4 2 4 5 5
Total Income 667 863 873 927 1,017 1,301 1,592 1,511 1,725 1,948
Total Expenditure -476 -642 -689 -745 -815 -1,054 -1,291 -1,234 -1,398 -1,602
PBIDT 190 221 184 183 202 246 300 277 328 345
Interest -60 -68 -60 -62 -48 -49 -58 -52 -36 -31
Depreciation -49 -55 -64 -67 -69 -86 -93 -82 -85 -96
Taxation -8 -34 -19 -12 -13 -34 -46 -42 -73 -58
Exceptional Items -48 -4 -15
PAT 25 64 40 41 68 77 103 84 133 161
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 25 64 40 41 68 77 103 84 133 161
Adjusted EPS 2 5 3 3 5 6 8 7 11 13

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 137 61 154 102 186 163 139 186 285 229
Cash Fr. Inv. -54 -28 -23 -43 -64 -102 -110 -125 -164 -156
Cash Fr. Finan. -87 -27 -124 -69 -124 -63 -25 -55 -101 -97
Net Change -4 6 7 -10 -2 -2 4 6 20 -24
Cash & Cash Eqvt 3 9 16 6 4 2 6 11 32 8

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 68.77 68.77 68.77 68.77 68.77 68.77 68.77 68.77 68.77
Public 31.23 31.23 31.23 31.23 31.23 31.23 31.23 31.23 31.23
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 10 Jun 2022
Related Party Transactions Pursuant To Regulation 23(9) Of The SEBI (LODR) Regulations 2015
Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the half-year ended March 31 2022
Thu, 09 Jun 2022
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Submission of transcript of Earnings call for quarter and financial year ended March 31 2022 under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015
Fri, 03 Jun 2022
Intimation Under Regulation 30 Of SEBI (LODR) - Earnings Call Audio Recording Q4 FY22
Intimation under Regulation 30 of SEBI (LODR) Regulations 2015 - Earnings call audio recording Q4 FY22

Technical Scans View Details

Fri, 24 Jun 2022
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Opening at Low Opening at Low
Closing Above Previous High Closing Above Previous High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 197,729.19 824.10 -0.1%
Divi's Laboratories Ltd. 97,465.46 3,671.45 +0.1%
Cipla Ltd. 75,288.48 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. 71,702.79 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. 55,150.04 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. 48,693.19 2,877.70 +0.8%
Gland Pharma Ltd. 42,987.55 2,610.75 +0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 60.42 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 32.92 3,671.45 +0.1%
Cipla Ltd. Consolidated 2022-03 29.92 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.85 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 52.24 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 62.67 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2022-03 35.48 2,610.75 +0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 4.12 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8.31 3,671.45 +0.1%
Cipla Ltd. Consolidated 2022-03 3.61 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.73 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 9.78 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8.18 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2022-03 6.01 2,610.75 +0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,671.45 +0.1%
Cipla Ltd. Consolidated 2021-03 0.10 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,610.75 +0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,671.45 +0.1%
Cipla Ltd. Consolidated 2021-03 14.13 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,610.75 +0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,671.45 +0.1%
Cipla Ltd. Consolidated 2021-03 14.13 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,610.75 +0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,671.45 +0.1%
Cipla Ltd. Consolidated 2021-03 19,159.59 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,610.75 +0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,671.45 +0.1%
Cipla Ltd. Consolidated 2021-03 2,401.30 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,610.75 +0.1%

FAQ's On Hikal Ltd.

Can I Buy Hikal Shares now?

What is the Share Price of Hikal?

What is the Relative Strength Index (RSI) Value of Hikal?

What is the Market Capital (MCAP) of Hikal?

What are the key metrics to analyse Hikal?

What is the Price Performance of Hikal?